RNAi Technology Market was valued at US$ 1,783.5 Mn in 2021 and is forecast to reach a value of US$ 3,506.5 Mn by 2028 at a CAGR of 10.1% between 2022 and 2028 | QIAGEN, Dicerna Pharmaceuticals Inc., Phio Pharmaceuticals Corp

Therapeutics based on RNAi (RNA interference) offer the potential to treat a number of ailments. Additionally, RNA interference (RNAi) has promise for the treatment of viral illnesses such hepatitis C virus (HCV) and human immunodeficiency virus (HIV) (HIV). Furthermore, RNAi is now frequently used in biological and biomedical research to examine the impact of preventing the expression of a particular gene. It is thought to be a highly specific method for gene silencing and has enormous potential for the treatment of numerous pathologic conditions, including cancer, viral infections, and cardiovascular diseases, among others.

Market Statistics

By the end of 2022, the market for RNAi technology is anticipated to be worth US$ 1,963.2 million.

To Get More Business Strategies Sample Copy of Report @ https://www.coherentmarketinsights.com/insight/request-sample/5281

Drivers

During the projected period, an increased focus on the development of RNAi therapies (RNAi-based treatments having the potential to treat a range of ailments) is anticipated to fuel the growth of the worldwide RNAi technology market. For instance, industry participants are spending a lot of money developing therapeutic RNAi. The Phase I clinical trial for the Company’s siRNA (small interfering RNA) therapeutic candidate, STP707, with intravenous (IV) administration in the United States for the treatment of solid tumours will begin in February 2022, according to a press release from Sirnaomics Ltd.

Opportunities

Global RNAi technology market participants should have significant growth prospects due to the rising incidence of cancer. For instance, the demand for efficient cancer therapies is rising quickly in tandem with the rising prevalence of cancer among the world’s population. One of the biggest health issues in the globe is cancer. The World Health Organization (WHO) reports that cancer was the biggest cause of death globally in 2020, accounting for close to 10 million deaths, or close to one in every six. In order to produce innovative (RNAi-based) cancer treatments and therapies, numerous pharmaceutical and biotechnology companies are making significant investments in research and development.

Restraints

The development of the worldwide RNAi technology market is anticipated to be hampered by strict laws and regulations as well as the unstable and potentially immunogenic nature of RNA. For instance, RNA-based treatments require unique delivery methods or chemical alterations to enable them to reach the minimal effective concentration due to the intrinsic instability of RNA. Furthermore, due to its immunogenicity and labile nature, mRNA cannot be used in therapeutic settings. In consequence, it is anticipated that this will impede market expansion. As a result, it is anticipated that the global market for RNAi technology will experience slow growth.

Impact

The COVID-19 (pandemic) outbreak is anticipated to have a substantial effect on market expansion. Therapeutics for COVID-19 are being created with the help of RNAi technology. RNAi against COVID-19 illness may be targeted at one or both of two different types of targets, such as viral proteins required for the survival and reproduction of SARS-CoV-2 and host components involved in the virus’s entry into and movement through cells. Additionally, three siRNA products have been given the thumbs-up by the U.S. Food and Drug Administration (FDA) for use in humans, raising great hopes for siRNA therapies for coronaviruses. The market for RNAi technology is then anticipated to grow as a result.

Key Takeaways

The market for RNAi technology was valued at US$ 1,783.5 Mn in 2021 and is anticipated to grow at a CAGR of 10.1% from 2022 to 2028 to reach US$ 3,506.5 Mn.

Inquire More Or Share Questions If Any Before The Purchase On This Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/5281

With a 98.5% market share in terms of value, the medication discovery and development application segment dominated the global RNAi technology market in 2021. Increasing product approval and launches are anticipated to fuel the segment’s expansion throughout the course of the forecast year.

Market Trends

As long as there is any clinical experience with long-term RNAi-based medicines, the potential for RNAi-based therapeutics is limitless. Globally, RNA-based medicinal research and development (R&D) activities are expanding as a result of abundant research funding, supportive governmental policies, and extensive R&D infrastructure. Throughout the projection period, it is anticipated that this tendency would persist, fueling market expansion.

Competitive Landscape

Thermo Fisher Scientific Inc., QIAGEN, Alnylam Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., SBI Biotech Co. Ltd., Ohio Pharmaceuticals Corp., Silence Therapeutics PLC, Arcturus Therapeutics, Benitec Biopharma Ltd., Ionis Pharmaceuticals Inc., and Sigma Aldrich are a few of the major companies active in the global RNAi technology market.

Recent Developments

A definitive deal between Thermo Fisher Scientific and Brammer Bio was signed in March 2019. As per this agreement, Thermo Fisher would buy Brammer Bio for USD 1.7 billion in cash.

A novel, investigational RNA interference (RNAi) therapy for the treatment of chronic hepatitis B virus (HBV) infection was introduced in November 2018 by Vir Biotechnology Inc. and Alnylam Pharmaceuticals Inc.

Purchase This Premium Report @ https://www.coherentmarketinsights.com/insight/buy-now/5281